Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASH 2019: Acalabrutinib Combination Therapy and Monotherapy in Treatment-Naive CLL
ABC Trial: Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
ASH 2019: Early Results With Multiplexed Genetic Engineering in Treating Multiple Myeloma
Atezolizumab/Chemotherapy Approved by FDA in First-Line Treatment of Metastatic Lung Cancer
Case Studies: Possible Link Between Nivolumab for Lung Cancer and Pericardial Effusion
IKCS 2019: Lenvatinib Plus Pembrolizumab in Subset of Patients With Kidney Cancer
Triplet Regimen for BRAF-Mutated Metastatic Melanoma
Final Overall Survival With Atezolizumab/Chemotherapy in Advanced Lung Cancer
IKCS 2019: Treatment-Free Survival With Immunotherapy Versus Sunitinib in Kidney Cancer
SITC 2019: Adding IL-2 Agonist to Nivolumab in Metastatic Melanoma
IKCS 2019: Histopathologic Changes Associated With Immunotherapy for Kidney Cancer
SITC 2019: Atezolizumab Monotherapy Versus Chemotherapy in PD-L1–Selected Lung Cancer
SITC 2019: Adenovirus Plus Pembrolizumab in Resistant Melanoma
SITC 2019: Avelumab Plus FOLFOX and Cetuximab in Metastatic Colorectal Cancer
Prognostic Value of Residual Lymphadenopathy After Chemoimmunotherapy for CLL
3-Year Survival Update of KEYNOTE-024: Comparison of Pembrolizumab and Chemotherapy
Nivolumab and Ipilimumab in Melanoma: OpACIN Trial Follow-up
Daratumumab Plus Triplet Therapy for Transplant-Eligible Patients With Multiple Myeloma
KEYNOTE-119 Trial of Pembrolizumab Versus Chemotherapy for Triple-Negative Breast Cancer
Personalization of Treatment Based on Fitness in Elderly Patients With Head/Neck Cancer
Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
Early-Phase Trial of New Monoclonal Antibody Plus Pembrolizumab in Resistant Myeloma
ESMO 2019: Neoadjuvant Talimogene Laherparepvec in Advanced Resectable Melanoma
ESMO 2019: Tissue Tumor Mutational Burden and Survival With Pembrolizumab in Lung Cancer
Using Minimal Residual Disease Detection to Monitor Outcomes in CLL Treatment
ESMO 2019: Cobimetinib Plus Atezolizumab Versus Pembrolizumab in BRAF V600 Wild-Type Melanoma
ESMO 2019: Monalizumab Monotherapy for Resistant Head/Neck Cancer
Advanced Non-Melanoma Skin Cancer: Systemic Treatment Update
ESMO 2019: Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
First-in-Human Study of CD200 Blockade With Samalizumab in CLL
ESMO 2019: Novel Mutated Genes May Alter Responses to Therapy in Colorectal Cancer
First-in-Human Trial of Anti-AXL Antibody-Drug Conjugate in Advanced Lung Cancer
ESMO 2019: Update From CheckMate 238 of Nivolumab Versus Ipilimumab in Advanced Melanoma
ESMO 2019: Olaparib Plus Bevacizumab as Maintenance Therapy for Ovarian Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.